Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m).
Marshall A, Levine M, Hill C, Hale D, Thirlwall J, Wilkie V, French K, Kakkar A, Lokare A, Maraveyas A, Chapman O, Arif A, Petrou S, Maredza M, Hobbs R, Dunn JA, Young AM. Marshall A, et al. Among authors: dunn ja. J Thromb Haemost. 2020 Apr;18(4):905-915. doi: 10.1111/jth.14752. Epub 2020 Feb 26. J Thromb Haemost. 2020. PMID: 31995662 Free article. Clinical Trial.
Pulmonary rehabilitation programme for patients undergoing curative lung cancer surgery.
Bradley A, Marshall A, Stonehewer L, Reaper L, Parker K, Bevan-Smith E, Jordan C, Gillies J, Agostini P, Bishay E, Kalkat M, Steyn R, Rajesh P, Dunn J, Naidu B. Bradley A, et al. Eur J Cardiothorac Surg. 2013 Oct;44(4):e266-71. doi: 10.1093/ejcts/ezt381. Epub 2013 Aug 19. Eur J Cardiothorac Surg. 2013. PMID: 23959742 Clinical Trial.
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. Ford HE, et al. Among authors: dunn ja. Lancet Oncol. 2014 Jan;15(1):78-86. doi: 10.1016/S1470-2045(13)70549-7. Epub 2013 Dec 10. Lancet Oncol. 2014. PMID: 24332238 Free article. Clinical Trial.
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P. Corrie PG, et al. Among authors: dunn ja. Lancet Oncol. 2014 May;15(6):620-30. doi: 10.1016/S1470-2045(14)70110-X. Epub 2014 Apr 15. Lancet Oncol. 2014. PMID: 24745696 Free article. Clinical Trial.
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
Stein RC, Dunn JA, Bartlett JM, Campbell AF, Marshall A, Hall P, Rooshenas L, Morgan A, Poole C, Pinder SE, Cameron DA, Stallard N, Donovan JL, McCabe C, Hughes-Davies L, Makris A; OPTIMA Trial Management Group. Stein RC, et al. Among authors: dunn ja. Health Technol Assess. 2016 Feb;20(10):xxiii-xxix, 1-201. doi: 10.3310/hta20100. Health Technol Assess. 2016. PMID: 26867046 Free PMC article. Clinical Trial.
280 results